FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label

被引：10
|
作者：
Ratner, Mark
机构：
来源：
NATURE BIOTECHNOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1038/nbt0717-606
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：606 / 607
页数：2
相关论文
共 34 条
  • [1] FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label
    Mark Ratner
    Nature Biotechnology, 2017, 35 : 606 - 606
  • [2] DRUG REPURPOSING FOR CYSTIC FIBROSIS SUBJECTS WITH RARE CFTR MUTATIONS
    Hagemeijer, M. C.
    de Poel, E.
    van Mourik, P.
    Vonk, A. M.
    Oppelaar, H.
    de Winter-de Groot, K. M.
    Heida-Michel, S.
    Geerdink, M.
    van der Ent, C. K.
    Beekman, J. M.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S316 - S317
  • [3] Improved QSAR model for cholestasis built with FDA drug label data
    Girireddy, M.
    Saiakhov, R.
    Chakravarti, S.
    TOXICOLOGY LETTERS, 2021, 350 : S165 - S165
  • [4] Gene Correction of Cystic Fibrosis Mutations In Vitro and In Vivo Mediated by PNA Nanoparticles
    Piotrowski-Daspit, Alexandra S.
    Barone, Christina
    Kauffman, Amy C.
    Lin, Chun-Yu
    Nguyen, Richard
    Gupta, Anisha
    Glazer, Peter M.
    Saltzman, W. Mark
    Egan, Marie E.
    MOLECULAR THERAPY, 2019, 27 (04) : 44 - 44
  • [5] PHARMACOKINETICS AND MODULATION OF LIPID KINETICS BY FENRETINIDE, A NEWLY FDA APPROVED ORPHAN DRUG FOR CYSTIC FIBROSIS
    Wojewodka, G.
    De Sanctis, J.
    Maurer, B. J.
    Hajduch, M.
    Radzioch, D.
    PEDIATRIC PULMONOLOGY, 2010, : 425 - 426
  • [6] Cystic fibrosis transmembrane regulator protein mutations: 'Class' opportunity for novel drug innovation
    MacDonald K.D.
    McKenzie K.R.
    Zeitlin P.L.
    Pediatric Drugs, 2007, 9 (1) : 1 - 10
  • [7] Simple triple-label detection of seven cystic fibrosis mutations by time-resolved fluorometry
    Heinonen, P
    Iitia, A
    Torresani, T
    Lovgren, T
    CLINICAL CHEMISTRY, 1997, 43 (07) : 1142 - 1150
  • [8] Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening
    Bobadilla, JL
    Macek, M
    Fine, JP
    Farrell, PM
    HUMAN MUTATION, 2002, 19 (06) : 575 - 606
  • [9] Challenges with drug efficacy prediction of in vitro models of biofilms infecting cystic fibrosis airway
    Sousa, Ana Margarida
    Pereira, Maria Olivia
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (06) : 635 - 638
  • [10] FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
    de Poel, E.
    Spelier, S.
    Hagemeijer, M. C.
    van Mourik, P.
    Suen, S. W. F.
    Vonk, A. M.
    Brunsveld, J. E.
    Ithakisiou, G. N.
    Kruisselbrink, E.
    Oppelaar, H.
    Berkers, G.
    de Groot, K. M. de Winter
    Heida-Michel, S.
    Jans, S. R.
    van Panhuis, H.
    Bakker, M.
    van der Meer, R.
    Roukema, J.
    Dompeling, E.
    Weersink, E. J. M.
    Koppelman, G. H.
    Blaazer, A. R.
    Muijlwijk-Koezen, J. E.
    van der Ent, C. K.
    Beekman, J. M.
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (03) : 548 - 559
1234